Why SV Health Investors’ EpiVax acquisition signals a bigger private equity push into immunogenicity services

SV Health Investors acquires EpiVax. Read why immunogenicity risk assessment is becoming a more strategic pharma services market.

SV Health Investors acquires EpiVax. Read why immunogenicity risk assessment is becoming a more strategic pharma services market.